Blog

John V. Oyler: Committed to uniting the global community against cancer as BeOne

BeiGene/LinkedIn

Nov 16, 2024, 11:27

John V. Oyler: Committed to uniting the global community against cancer as BeOne

John V. Oyler, Founder, Chairman & CEO at BeiGene, shared a post by BeiGene on LinkedIn, adding the following:

“We must all work together, which is why we are committed to uniting the global community against cancer as BeOne. Learn more about our proposed company name change by reading the press release below.”

Quoting BeiGene’s post:

“Today we unveiled our proposed name change to BeOne Medicines Ltd. Reaffirming our mission to unite the global community against cancer. Read the press release for full details.”

BeiGene BeOne Medicines Biopharma cancer cancer care Cancer research cancer treatment clinical trials drug development global community global oncology healthcare Healthcare Partnerships OncoDaily Oncology oncology research patient care pharmaceutical innovation

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer